Cargando…
Clinical outcome measures following plasma exchange for MG exacerbation
Our objective is to report longitudinal results of the MG‐ADL, MG‐Composite, MG‐MMT, and MG‐QoL15 in an open‐label trial of therapeutic plasma exchange in myasthenia gravis. Ten MG patients experiencing exacerbation had assessments prior to, immediately following, and at selected time points post‐TP...
Autores principales: | Raja, Shruti M., Howard, James F., Juel, Vern C., Massey, Janice M., Chopra, Manisha, Guptill, Jeffrey T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801175/ https://www.ncbi.nlm.nih.gov/pubmed/31560178 http://dx.doi.org/10.1002/acn3.50901 |
Ejemplares similares
-
B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity
por: Yi, John S., et al.
Publicado: (2017) -
Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007) -
Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
por: Masi, Gianvito, et al.
Publicado: (2023) -
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis
por: Guptill, Jeffrey T., et al.
Publicado: (2015) -
Therapeutic Plasma Exchange Practices in Intensive Care Unit
por: Ranganathan, Lakshmi, et al.
Publicado: (2019)